Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/advances-in-chemotherapy-for-pancreatic-cancer-6sTMEup0tp
References (97)
-
U. Pelzer, I. Schwaner, J. Stieler, M. Adler, J. Seraphin, B. Dörken, H. Riess, H. Oettle (2011)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.European journal of cancer, 47 11
-
Hidehisa Yamada, S. Hirano, Eiichi Tanaka, T. Shichinohe, S. Kondo (2006)
Surgical treatment of liver metastases from pancreatic cancer.HPB : the official journal of the International Hepato Pancreato Biliary Association, 8 2
-
D. Palmer, D. Stocken, H. Hewitt, C. Markham, A. Hassan, P. Johnson, John Buckels, S. Bramhall (2007)
A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with CisplatinAnnals of Surgical Oncology, 14
-
J. Klempnauer, G. Ridder, P. Piso, R. Pichlmayr (1996)
[Is liver resection in metastases of exocrine pancreatic carcinoma justified?].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 67 4
-
S. Yamada, T. Fujii, H. Sugimoto, N. Kanazumi, H. Kasuya, S. Nomoto, S. Takeda, Y. Kodera, A. Nakao (2009)
Pancreatic cancer with distant metastases: a contraindication for radical surgery?Hepato-gastroenterology, 56 91-92
-
S. Mukherjee, C. Hurt, J. Bridgewater, S. Falk, S. Cummins, H. Wasan, T. Crosby, C. Jephcott, R. Roy, G. Radhakrishna, A. Mcdonald, R. Ray, G. Joseph, J. Staffurth, R. Abrams, G. Griffiths, T. Maughan (2013)
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trialThe Lancet. Oncology, 14
-
C. Kang, Y. Chung, J. Park, J. Sung, H. Hwang, H. Choi, Hyunki Kim, S. Song, W. Lee (2012)
Potential Contribution of Preoperative Neoadjuvant Concurrent Chemoradiation Therapy on Margin-Negative Resection in Borderline Resectable Pancreatic CancerJournal of Gastrointestinal Surgery, 16
-
Jae-Lyun Lee, Song-Cheol Kim, Jihoon Kim, S. Lee, Tae‐Won Kim, D. Park, D. Seo, S. Lee, Myung-Hwan Kim, Jong Kim, Jin-hong Park, S. Shin, D. Han (2012)
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.Surgery, 152 5
-
Y. Chun, B. Milestone, J. Watson, S. Cohen, B. Burtness, P. Engstrom, O. Haluszka, Jeffrey Tokar, M. Hall, C. Denlinger, I. Astsaturov, J. Hoffman (2010)
Defining Venous Involvement in Borderline Resectable Pancreatic CancerAnnals of Surgical Oncology, 17
-
B. Schneider, K. Ganjoo, D. Seitz, J. Picus, F. Fata, C. Stoner, C. Calley, P. Loehrer (2003)
Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group StudyOncology, 65
-
J. Kharofa, T. Kelly, P. Ritch, B. George, L. Wiebe, James Thomas, K. Christians, Douglas Evans, B. Erickson (2012)
5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.Journal of Clinical Oncology, 30
-
GJ Ridder J Klempnauer (1996)
Is liver resection in metastases of exocrine pancreatic carcinoma justified?Chir Z Für Alle Geb Oper Medizen, 67
-
Seung Kim, Joon-Oh Park, Jeeyun Lee, Kyu Lee, J. Lee, S. Choi, J. Heo, Y. Park, W. Kang, Keunchil Park (2006)
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancerCancer, 106
-
(2009)
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. -
B. Boone, S. Sabbaghian, M. Zenati, J. Marsh, A. Moser, A. Zureikat, A. Singhi, H. Zeh, A. Krasinskas (2014)
Loss of SMAD4 staining in pre‐operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancerJournal of Surgical Oncology, 110
-
T. Takada, Hodaka Amano, H. Yasuda, Y. Nimura, T. Matsushiro, H. Kato, T. Nagakawa, T. Nakayama (2002)
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?Cancer, 95
-
A. Fukutomi, K. Uesaka, N. Boku, H. Kanemoto, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, Takayuki Nakamura, M. Kanai, S. Hirano, Y. Yoshikawa, Y. Ohashi (2013)
JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.Journal of Clinical Oncology, 31
-
K. Shimada, T. Kosuge, J. Yamamoto, S. Yamasaki, M. Sakamoto (2004)
Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis.Hepato-gastroenterology, 51 56
-
M. Chuong, T. Hayman, M. Patel, M. Russell, M. Malafa, P. Hodul, G. Springett, Junsung Choi, R. Shridhar, S. Hoffe (2011)
Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.Gastrointestinal cancer research : GCR, 4 4
-
D. Goldstein, Robert Maraghi, P. Hammel, V. Heinemann, V. Kunzmann, J. Sastre, W. Scheithauer, S. Siena, J. Tabernero, L. Teixeira, G. Tortora, J. Laethem, R. Young, Xinyu Wei, B. Lu, A. Romano, D. Hoff (2014)
Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.Journal of Clinical Oncology, 32
-
R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schüller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, C. Köhne, W. Mingrone, S. Stemmer, K. Tamas, G. Kornek, D. Koeberle, S. Cina, J. Bernhard, D. Dietrich, W. Scheithauer (2007)
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 16
-
K. Christians, S. Tsai, A. Mahmoud, P. Ritch, James Thomas, L. Wiebe, T. Kelly, B. Erickson, Huamin Wang, Douglas Evans, B. George (2014)
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?The oncologist, 19 3
-
D. Yardley (2013)
nab-Paclitaxel mechanisms of action and delivery.Journal of controlled release : official journal of the Controlled Release Society, 170 3
-
Malcolm, J. Moore, John Andersen, Mark Green, M. Rothenberg, M. Modiano, M. Cripps, Russell, K. Portenoy, A. Storniolo, Peter Tarassoff, Robert Nelson, F. Dorr, C. Stephens, Daniel, D., Von Hoff (1997)
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
-
S. Bayraktar, C. Rocha-Lima (2010)
Advanced or metastatic pancreatic cancer: molecular targeted therapies.The Mount Sinai journal of medicine, New York, 77 6
-
E. Poplin, Yang Feng, J. Berlin, M. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'dwyer, D. Haller, P. Catalano, D. Cella, A. Benson (2009)
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 23
-
Hidenori Takahashi, H. Ohigashi, K. Gotoh, S. Marubashi, Terumasa Yamada, M. Murata, T. Ioka, H. Uehara, M. Yano, O. Ishikawa (2013)
Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic CancerAnnals of Surgery, 258
-
T. Seufferlein, J. Bachet, E. Cutsem, P. Rougier (2012)
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 7
-
R. Thota, L. Goff, E. Chan, J. Berlin, C. Jones, Pamela McClanahan, G. Ayers, D. Cardin (2014)
A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).Journal of Clinical Oncology, 32
-
S. Shrikhande, J. Kleeff, C. Reiser, J. Weitz, U. Hinz, I. Esposito, Jan Schmidt, H. Friess, M. Büchler (2006)
Pancreatic Resection for M1 Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology, 14
-
J. Neoptolemos, Pat Baker, H. Beger, K. Link, P. Pederzoli, C. Bassi, C. Dervenis, H. Friess, M. Büchler (1997)
Progress report: A randomized multicenter European stydy comparing adjuvant radiotherapy, 6 Mo chemotherapy, and combination therapy vs No-adjuvant treatment in resectable pancreatic cancer (ESPAC-1)International Journal of Pancreatology, 21
-
J. Neoptolemos, D. Stocken, H. Friess, C. Bassi, J. Dunn, H. Hickey, H. Beger, L. Fernández‐Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, Á. Pap, D. Spooner, D. Kerr, M. Büchler (2004)
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.The New England journal of medicine, 350 12
-
K. Menon, D. Gomez, A. Smith, A. Anthoney, C. Verbeke (2009)
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).HPB : the official journal of the International Hepato Pancreato Biliary Association, 11 1
-
G. Heestand, James Murphy, J. Moughan, W. Regine, Jia Luo, M. Graber, P. Kunz, G. Fisher, C. Guha, B. Lin, R. Mowat, R. Gaur, M. Buyyounouski, Yuhchyau Chen, D. Chang, A. Koong (2014)
A novel biomarker panel examining response to adjuvant pancreatic cancer therapy in RTOG 9704.Journal of Clinical Oncology, 32
-
H. Ueno, T. Kosuge, Y. Matsuyama, J. Yamamoto, A. Nakao, S. Egawa, R. Doi, M. Monden, T. Hatori, Masao Tanaka, Mitsuo Shimada, K. Kanemitsu (2009)
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBritish Journal of Cancer, 101
-
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. Raoul, S. Gourgou-Bourgade, C. Fouchardière, J. Bennouna, J. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux (2011)
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.The New England journal of medicine, 364 19
-
J. Valle, D. Palmer, R. Jackson, T. Cox, J. Neoptolemos, P. Ghaneh, C. Rawcliffe, C. Bassi, D. Stocken, D. Cunningham, D. O’reilly, D. Goldstein, B. Robinson, C. Karapetis, A. Scarfe, F. Lacaine, J. Sand, J. Izbicki, J. Mayerle, C. Dervenis, A. Oláh, G. Butturini, P. Lind, M. Middleton, A. Anthoney, K. Sumpter, Ross Carter, M. Büchler (2014)
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 6
-
A. Gracián, M. Jameson, E. Grande, P. Cooray, F. Parnis, P. Grimison, M. Jeffery, R. Stagg, J. Dupont, N. Tebbutt (2014)
A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.Journal of Clinical Oncology, 32
-
C. Iacobuzio-Donahue, Baojin Fu, S. Yachida, Mingde Luo, H. Abe, Clark Henderson, F. Vilardell, Z. Wang, J. Keller, P. Banerjee, J. Herman, J. Cameron, C. Yeo, M. Halushka, J. Eshleman, M. Raben, A. Klein, R. Hruban, M. Hidalgo, D. Laheru (2009)
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 11
-
M. Moore, D. Goldstein, J. Hamm, A. Figer, J. Hecht, S. Gallinger, H. Au, P. Murawa, D. Walde, R. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, Mieke Ptasynski, W. Parulekar (2023)
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 41
-
J. Neoptolemos, Deborah Stocken, Claudio Bassi, P. Ghaneh, David Cunningham, David Goldstein, Robert Padbury, M. Moore, Steven Gallinger, Christophe Mariette, M. Wente, J. Izbicki, Helmut Friess, M. Lerch, C. Dervenis, Attila Oláh, G. Butturini, R. Doi, P. Lind, David Smith, Juan Valle, Daniel Palmer, John Buckels, Joyce Thompson, Colin McKay, C. Rawcliffe, M. Büchler (2010)
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.JAMA, 304 10
-
G. Varadhachary, R. Wolff, C. Crane, Charlotte Sun, Jeffrey Lee, P. Pisters, J. Vauthey, E. Abdalla, Huamin Wang, G. Staerkel, Jeffrey Lee, W. Ross, E. Tamm, P. Bhosale, S. Krishnan, P. Das, L. Ho, H. Xiong, J. Abbruzzese, Douglas Evans (2008)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
-
K. Sahora, I. Kuehrer, M. Schindl, C. Koelblinger, P. Goetzinger, M. Gnant (2011)
NeoGemTax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic CancerWorld Journal of Surgery, 35
-
S. Shrikhande, S. Arya, S. Barreto, Sachin Ingle, M. D'Souza, Rohini Hawaldar, P. Shukla (2011)
Borderline resectable pancreatic tumors: is there a need for further refinement of this stage?Hepatobiliary & pancreatic diseases international : HBPD INT, 10 3
-
J. Cameron, T. Riall, J. Coleman, Kenneth Belcher (2006)
One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 244
-
F. Spitz, J. Abbruzzese, Jeffrey Lee, P. Pisters, A. Lowy, C. Fenoglio, K. Cleary, N. Janjan, M. Goswitz, T. Rich, D. Evans (1997)
Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 3
-
K. Uesaka, A. Fukutomi, N. Boku, H. Kanemoto, M. Konishi, I. Matsumoto, Y. Kaneoka, Y. Shimizu, S. Nakamori, H. Sakamoto, S. Morinaga, O. Kainuma, K. Imai, N. Sata, S. Hishinuma, Takayuki Nakamura, M. Kanai, S. Hirano, Y. Yoshikawa, Y. Ohashi (2013)
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study).Journal of Clinical Oncology, 31
-
C. Crane, G. Varadhachary, J. Yordy, G. Staerkel, M. Javle, H. Safran, W. Haque, B. Hobbs, S. Krishnan, J. Fleming, P. Das, Jeffrey Lee, J. Abbruzzese, R. Wolff (2011)
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 22
-
G. Butturini, D. Stocken, M. Wente, H. Jeekel, J. Klinkenbijl, K. Bakkevold, T. Takada, H. Amano, C. Dervenis, C. Bassi, M. Büchler, J. Neoptolemos (2008)
Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.Archives of surgery, 143 1
-
P. Loehrer, Yang Feng, H. Cárdenes, L. Wagner, J. Brell, D. Cella, P. Flynn, R. Ramanathan, C. Crane, S. Alberts, A. Benson (2011)
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 31
-
Neoptolemos European Study Group for Pancreatic Cancer
combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. http://www.isrctn.com/ISRCTN9639743422 -
S. Yamada, A. Nakao, T. Fujii, H. Sugimoto, N. Kanazumi, S. Nomoto, Y. Kodera, S. Takeda (2009)
Pancreatic Cancer With Paraaortic Lymph Node Metastasis: A Contraindication for Radical Surgery?Pancreas, 38
-
H. Takamori, T. Hiraoka, K. Kanemitsu, Tatsuya Tsuji, N. Saito, H. Nishida, H. Sakaguchi, Y. Miyauchi (1994)
Treatment Strategies for Hepatic Metastases From Pancreatic Cancer in Patients Previously Treated With Radical Resection Combined With Intraoperative Radiation TherapyHPB Surgery, 8
-
J. Laethem, P. Hammel, F. Mornex, D. Azria, G. Tienhoven, P. Vergauwe, M. Peeters, M. Polus, M. Praet, M. Mauer, L. Collette, V. Budach, M. Lutz, E. Cutsem, K. Haustermans (2010)
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 29
-
S. Bramhall, J. Schulz, J. Nemunaitis, P. Brown, M. Baillet, John Buckels (2002)
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish Journal of Cancer, 87
-
Gastrointestinal Tumor Study Group (1988)
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone -
atthew Katz, P. Pisters, Douglas Evans, harlotte Sun, Jeffrey Lee, J. Fleming, N. Vauthey, E. Abdalla, C. Crane, obert Wolff, G. Varadhachary, R. Hwang (2008)
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.Journal of the American College of Surgeons, 206 5
-
F. Huguet, T. André, P. Hammel, P. Artru, J. Balosso, F. Selle, E. Deniaud-Alexandre, P. Ruszniewski, E. Touboul, R. Labianca, A. Gramont, C. Louvet (2007)
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 3
-
B. Chauffert, F. Mornex, F. Bonnetain, P. Rougier, C. Mariette, O. Bouché, J. Bosset, T. Aparicio, L. Mineur, A. Azzedine, P. Hammel, J. Butel, N. Stremsdoerfer, P. Maingon, L. Bedenne (2008)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.Annals of oncology : official journal of the European Society for Medical Oncology, 19 9
-
K. Bakkevold, B. Arnesjø, O. Dahl, B. Kambestad (1993)
Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study.European journal of cancer, 29A 5
-
Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma
An Intergroup Single-Arm Pilot Study. https://clinicaltrials.gov/ct2/show/NCT01821612 -
Hazel Jj, Thirlwell Mp, M. Huggins, A. Maksymiuk, MacFarlane Jk (1981)
Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.Journal of the Canadian Association of Radiologists, 32 3
-
Y. Chua, C. Karapetis, V. Gebski, R. O’Connell, S. Begbie, L. Nott, M. Cronk, C. Underhill, E. Abdi, T. Hagen, N. Wong, M. Hall, D. Ferraro, K. Sjoquist, Cheryl Santos, J. Mackey, D. Goldstein (2014)
Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.Journal of Clinical Oncology, 32
-
H. Ueno, T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, N. Boku, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, M. Sho, M. Kitano, A. Cheng, K. Mizumoto, Jen‐Shi Chen, J. Furuse, A. Funakoshi, T. Hatori, Taketo Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, T. Okusaka, Masao Tanaka (2013)
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 13
-
G. Barugola, S. Partelli, S. Crippa, P. Capelli, M. D’Onofrio, P. Pederzoli, M. Falconi (2012)
Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.American journal of surgery, 203 2
-
K. Bilimoria, D. Bentrem, C. Ko, J. Ritchey, A. Stewart, D. Winchester, M. Talamonti (2007)
Validation of the 6th edition AJCC pancreatic cancer staging systemCancer, 110
-
T. Kosuge, T. Kiuchi, K. Mukai, T. Kakizoe (2006)
A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.Japanese journal of clinical oncology, 36 3
-
D Goldstein MJ Moore (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol Off J Am Soc Clin Oncol, 25
-
R. Bold (2013)
RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative TherapyAnnals of Surgical Oncology, 20
-
F. Motoi, K. Ishida, F. Fujishima, Shigeru Ottomo, M. Oikawa, T. Okada, H. Shimamura, S. Takemura, Fuminori Ono, M. Akada, K. Nakagawa, Y. Katayose, S. Egawa, M. Unno (2013)
Neoadjuvant Chemotherapy with Gemcitabine and S-1 for Resectable and Borderline Pancreatic Ductal Adenocarcinoma: Results from a Prospective Multi-institutional Phase 2 TrialAnnals of Surgical Oncology, 20
-
C. Louvet, R. Labianca, P. Hammel, G. Lledo, M. Zampino, T. André, A. Zaniboni, M. Ducreux, E. Aitini, J. Taieb, R. Faroux, C. Lepère, A. Gramont (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
-
C. Michalski, M. Erkan, N. Hüser, M. Müller, M. Hartel, H. Friess, J. Kleeff (2009)
Resection of Primary Pancreatic Cancer and Liver Metastasis: A Systematic ReviewDigestive Surgery, 25
-
J. Faris, J. Wo (2013)
The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.The oncologist, 18 9
-
P. Sanjay, K. Takaori, S. Govil, S. Shrikhande, J. Windsor, J. Windsor (2012)
‘Artery‐first’ approaches to pancreatoduodenectomyBritish Journal of Surgery, 99
-
G. Colucci, R. Labianca, F. Costanzo, V. Gebbia, G. Cartenì, B. Massidda, E. Dapretto, L. Manzione, E. Piazza, M. Sannicolò, M. Ciaparrone, L. Cavanna, F. Giuliani, E. Maiello, A. Testa, P. Pederzoli, M. Falconi, C. Gallo, M. Maio, F. Perrone (2010)
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
-
W. Regine, K. Winter, R. Abrams, H. Safran, J. Hoffman, A. Konski, A. Benson, J. Macdonald, T. Rich, C. Willett (2011)
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III TrialAnnals of Surgical Oncology, 18
-
G. Varadhachary, E. Tamm, J. Abbruzzese, H. Xiong, C. Crane, Huamin Wang, Jeffrey Lee, P. Pisters, Douglas Evans, R. Wolff (2006)
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 13
-
F. Leone, M. Gatti, P. Massucco, F. Colombi, E. Sperti, D. Campanella, D. Regge, P. Gabriele, L. Capussotti, M. Aglietta (2013)
Induction gemcitabine and oxaliplatin therapy followed by a twice‐weekly infusion of gemcitabine and concurrent external‐beam radiation for neoadjuvant treatment of locally advanced pancreatic cancerCancer, 119
-
S. Morinaga, Yoshiyasu Nakamura, Yusuke Katayama, S. Sawazaki, K. Numata, K. Higuchi, T. Godai, M. Shiozawa, Y. Miyagi, S. Ohkawa, K. Yoichi, M. Akaike (2014)
MicroRNA-21 ISH analysis to predict DFS in pancreatic cancer patients undergoing adjuvant gemcitabine after curative surgery.Journal of Clinical Oncology, 32
-
S. Heinrich, B. Pestalozzi, M. Schäfer, A. Weber, P. Bauerfeind, A. Knuth, P. Clavien (2008)
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 15
-
H. Oettle, P. Neuhaus, A. Hochhaus, J. Hartmann, K. Gellert, K. Ridwelski, M. Niedergethmann, C. Zülke, J. Fahlke, M. Arning, M. Sinn, A. Hinke, H. Riess (2013)
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.JAMA, 310 14
-
Douglas Evans, G. Varadhachary, C. Crane, Charlotte Sun, Jeffrey Lee, P. Pisters, J. Vauthey, Huamin Wang, K. Cleary, G. Staerkel, C. Charnsangavej, Elizabeth Lano, L. Ho, R. Lenzi, J. Abbruzzese, R. Wolff (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
-
W. Hartwig, O. Strobel, U. Hinz, S. Fritz, T. Hackert, C. Roth, M. Büchler, J. Werner (2013)
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 20
-
R. McClaine, A. Lowy, J. Sussman, N. Schmulewitz, D. Grisell, Syed Ahmad (2010)
Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.HPB : the official journal of the International Hepato Pancreato Biliary Association, 12 1
-
J. Stokes, N. Nolan, E. Stelow, D. Walters, G. Weiss, E. Lange, T. Rich, R. Adams, T. Bauer (2011)
Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic CancerAnnals of Surgical Oncology, 18
-
Wei-Chih Liao, K. Chien, Yu-Lin Lin, Ming-Shiang Wu, Jaw-Town Lin, Hsiu‐Po Wang, Y. Tu (2013)
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.The Lancet. Oncology, 14 11
-
V. Heinemann, S. Boeck, A. Hinke, R. Labianca, C. Louvet (2008)
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer, 8
-
D. Hoff, R. Ramanathan, M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, V. Trieu, J. Iglesias, Hui Zhang, P. Soon-Shiong, T. Shi, N. Rajeshkumar, A. Maitra, M. Hidalgo (2011)
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 34
-
E. James, Xiaopan Yao, X. Cong, Jia Li, C. Hahn, Kristin Kaley, J. Kortmansky, N. Fischbach, B. Chang, R. Salem, Charles Cha, S. Stein, H. Hochster, J. Lacy (2014)
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).Journal of Clinical Oncology, 32
-
A. Jesus-Acosta, P. O'dwyer, R. Ramanathan, D. Hoff, A. Maitra, Z. Rasheed, Lei Zheng, N. Rajeshkumar, D. Le, A. Hoering, V. Bolejack, S. Yabuuchi, D. Laheru (2014)
A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).Journal of Clinical Oncology, 32
-
G. Stathopoulos, K. Syrigos, G. Aravantinos, A. Polyzos, P. Papakotoulas, G. Fountzilas, A. Potamianou, N. Ziras, J. Boukovinas, J. Varthalitis, N. Androulakis, A. Kotsakis, G. Samonis, V. Georgoulias (2006)
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish Journal of Cancer, 95
-
F. Huguet, J. Laethem, D. Goldstein, B. Glimelius, P. Artru, I. Borbath, O. Bouché, J. Shannon, T. André, L. Mineur, B. Chibaudel, F. Bonnetain, C. Louvet (2013)
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 18_suppl
-
P. Hosein, J. Macintyre, C. Kawamura, J. Maldonado, V. Ernani, A. Loaiza-Bonilla, G. Narayanan, A. Ribeiro, L. Portelance, J. Merchan, J. Levi, C. Rocha-Lima (2012)
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinomaBMC Cancer, 12
-
D. Cunningham, I. Chau, D. Stocken, J. Valle, David Smith, W. Steward, P. Harper, J. Dunn, C. Tudur-Smith, J. West, S. Falk, A. Crellin, F. Adab, J. Thompson, P. Leonard, J. Ostrowski, M. Eatock, W. Scheithauer, R. Herrmann, J. Neoptolemos (2009)
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
B. Park, Yoon Kim, J. Park, Seungmin Bang, Seung Park, J. Chung, K. Kim, J. Choi, W. Lee, S. Song (2006)
Phase II study of gemcitabine and cisplatin in advanced biliary tract cancerJournal of Gastroenterology and Hepatology, 21
-
D. Klaassen, J. Macintyre, G. Catton, P. Engstrom, C. Moertel (1985)
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 3 3
-
D. Le, A. Wang-Gillam, V. Picozzi, T. Greten, T. Crocenzi, G. Springett, M. Morse, H. Zeh, D. Cohen, R. Fine, Beth Onners, J. Uram, D. Laheru, A. Murphy, J. Skoble, E. Lemmens, J. Grous, Thomas Dubensky, D. Brockstedt, E. Jaffee (2014)
A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.Journal of Clinical Oncology, 32
- Publisher
- Springer Journals
- Copyright
- 2015 Indian Association of Surgical Oncology
- ISSN
- 0975-7651
- eISSN
- 0976-6952
- DOI
- 10.1007/s13193-014-0371-y
- Publisher site
- See Article on Publisher Site
Abstract
Abstract Pancreatic cancer remains challenging to treat. Over the past decade, there have been some major improvements in systemic therapy. Gemcitabine remains the key drug for both early and advanced cancer but combination chemotherapy is emerging as a new paradigm for patients with good performance status. This review focuses on current chemotherapy status for patients with pancreatic cancer.
Journal
Indian Journal of Surgical Oncology – Springer Journals
Published: Mar 1, 2015
Keywords: surgical oncology; oncology; surgery